Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood-brain barrier using MRI-guided focused ultrasound.

The blood-brain barrier (BBB) presents a significant obstacle for the treatment of many central nervous system (CNS) disorders, including invasive brain tumors, Alzheimer's, Parkinson's and stroke. Therapeutics must be capable of bypassing the BBB and also penetrate the brain parenchyma to achieve a desired effect within the brain. In this study, we test the unique combination of a non-invasive approach to BBB permeabilization with a therapeutically relevant polymeric nanoparticle platform capable of rapidly penetrating within the brain microenvironment. MR-guided focused ultrasound (FUS) with intravascular microbubbles (MBs) is able to locally and reversibly disrupt the BBB with submillimeter spatial accuracy. Densely poly(ethylene-co-glycol) (PEG) coated, brain-penetrating nanoparticles (BPNs) are long-circulating and diffuse 10-fold slower in normal rat brain tissue compared to diffusion in water. Following intravenous administration of model and biodegradable BPNs in normal healthy rats, we demonstrate safe, pressure-dependent delivery of 60nm BPNs to the brain parenchyma in regions where the BBB is disrupted by FUS and MBs. Delivery of BPNs with MR-guided FUS has the potential to improve efficacy of treatments for many CNS diseases, while reducing systemic side effects by providing sustained, well-dispersed drug delivery into select regions of the brain.

[1]  W. O’Brien,et al.  Influence of microbubble size on postexcitation collapse thresholds for single ultrasound contrast agents using double passive cavitation detection - [Letters] , 2013, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.

[2]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[3]  V. Camus,et al.  Mechanisms of antidepressant resistance , 2013, Front. Pharmacol..

[4]  Katherine W Ferrara,et al.  Acoustic response of compliable microvessels containing ultrasound contrast agents , 2006, Physics in medicine and biology.

[5]  Mu-Yi Hua,et al.  Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. , 2010, Radiology.

[6]  Rajiv Chopra,et al.  Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid-β Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease , 2010, PloS one.

[7]  Chih-Kuang Yeh,et al.  Ultrasound microbubble contrast agents for diagnostic and therapeutic applications: current status and future design. , 2012, Chang Gung medical journal.

[8]  Junru Wu,et al.  Ultrasound, cavitation bubbles and their interaction with cells. , 2008, Advanced drug delivery reviews.

[9]  S. Kulkarni,et al.  Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier. , 2011, Nanomedicine.

[10]  Ferenc A. Jolesz,et al.  Local and reversible blood–brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications , 2005, NeuroImage.

[11]  Natalia Vykhodtseva,et al.  Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. , 2012, Ultrasound in medicine & biology.

[12]  Nico de Jong,et al.  Ultrasound and Microbubble-Targeted Delivery of Macromolecules Is Regulated by Induction of Endocytosis and Pore Formation , 2009, Circulation research.

[13]  J. Kreuter,et al.  Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model , 2006, Journal of microencapsulation.

[14]  K. Hynynen,et al.  Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. , 2001, Radiology.

[15]  N. Jong,et al.  Ultrasound microbubble induced endothelial cell permeability. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[16]  T. Park,et al.  Biodegradable Nanoparticles Containing Doxorubicin-PLGA Conjugate for Sustained Release , 1999, Pharmaceutical Research.

[17]  Robert Langer,et al.  Nanoparticle technologies for cancer therapy. , 2010, Handbook of experimental pharmacology.

[18]  Justin Hanes,et al.  Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus , 2007, Proceedings of the National Academy of Sciences.

[19]  Yao-Sheng Tung,et al.  Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo. , 2010, Ultrasound in medicine & biology.

[20]  A. Wunder,et al.  Imaging blood–brain barrier dysfunction in animal disease models , 2012, Epilepsia.

[21]  R. Müller,et al.  Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Liang Jiang,et al.  Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model , 2009, Brain Research.

[23]  Pieter Wesseling,et al.  Diffuse glioma growth: a guerilla war , 2007, Acta Neuropathologica.

[24]  K. Hynynen,et al.  A three-dimensional model of an ultrasound contrast agent gas bubble and its mechanical effects on microvessels , 2012, Physics in medicine and biology.

[25]  Charles Nicholson,et al.  In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Stuart Moir,et al.  Safety of Contrast Agent Use During Stress Echocardiography in Patients With Elevated Right Ventricular Systolic Pressure: A Cohort Study , 2010, Circulation. Cardiovascular imaging.

[27]  K. Avgoustakis,et al.  Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. , 2004, Current drug delivery.

[28]  W. Pardridge.  Blood-brain barrier drug targeting: the future of brain drug development. , 2003, Molecular interventions.

[29]  Elizabeth Nance,et al.  A Dense Poly(Ethylene Glycol) Coating Improves Penetration of Large Polymeric Nanoparticles Within Brain Tissue , 2012, Science Translational Medicine.

[30]  F. Turkheimer,et al.  A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. , 2009, Cancer research.

[31]  Kazunori Kataoka,et al.  PEGylated Nanoparticles for Biological and Pharmaceutical Applications , 2003 .

[32]  L. Edvinsson,et al.  The Blood-Brain Barrier in Migraine Treatment , 2008, Cephalalgia : an international journal of headache.

[33]  Yunhui Liu,et al.  Mechanism of Low-Frequency Ultrasound in Opening Blood–Tumor Barrier by Tight Junction , 2011, Journal of Molecular Neuroscience.

[34]  Otto Kamp,et al.  Ultrasound and microbubble-induced intra- and intercellular bioeffects in primary endothelial cells. , 2009, Ultrasound in medicine & biology.

[35]  C. Deng,et al.  Improving ultrasound gene transfection efficiency by controlling ultrasound excitation of microbubbles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Lothar Lilge,et al.  Drug delivery to the brain by focused ultrasound induced blood-brain barrier disruption: quantitative evaluation of enhanced permeability of cerebral vasculature using two-photon microscopy. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[37]  C. Nicholson,et al.  Diffusion in brain extracellular space. , 2008, Physiological reviews.

[38]  Fabian Kiessling,et al.  Ultrasound Microbubbles for Molecular Diagnosis, Therapy, and Theranostics , 2012, The Journal of Nuclear Medicine.

[39]  A. Kim,et al.  Markedly enhanced skeletal muscle transfection achieved by the ultrasound-targeted delivery of non-viral gene nanocarriers with microbubbles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[40]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[41]  W. Pardridge,et al.  Blood-brain barrier genomics. , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  Jameel A Feshitan,et al.  Microbubble size isolation by differential centrifugation. , 2009, Journal of colloid and interface science.

[43]  Elisa E. Konofagou,et al.  Optimization of the Ultrasound-Induced Blood-Brain Barrier Opening , 2012, Theranostics.

[44]  K. Hynynen,et al.  Focused ultrasound delivery of Raman nanoparticles across the blood-brain barrier: potential for targeting experimental brain tumors. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[45]  Kullervo Hynynen,et al.  Brain arterioles show more active vesicular transport of blood-borne tracer molecules than capillaries and venules after focused ultrasound-evoked opening of the blood-brain barrier. , 2006, Ultrasound in medicine & biology.

[46]  F. Balis,et al.  Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Temozolomide in Non-human Primates , 2003, Journal of Neuro-Oncology.

[47]  M. Wintermark,et al.  High and Low Molecular Weight Fluorescein Isothiocyanate (FITC)–Dextrans to Assess Blood-Brain Barrier Disruption: Technical Considerations , 2010, Translational Stroke Research.

[48]  H. Shalev,et al.  Blood–brain barrier dysfunction in brain diseases: Clinical experience , 2012, Epilepsia.

[49]  K. Hynynen,et al.  MRI investigation of the threshold for thermally induced blood–brain barrier disruption and brain tissue damage in the rabbit brain , 2004, Magnetic resonance in medicine.

[50]  Natalia Vykhodtseva,et al.  Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. , 2012, Cancer research.

[51]  R. Donehower,et al.  Temozolomide in Patients with Advanced Cancer: Phase I and Pharmacokinetic Study , 2004, Pharmacotherapy.

[52]  J. Tu,et al.  Investigation on the inertial cavitation threshold and shell properties of commercialized ultrasound contrast agent microbubbles. , 2013, The Journal of the Acoustical Society of America.

[53]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[54]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[55]  Kullervo Hynynen,et al.  Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. , 2008, Ultrasound in medicine & biology.

[56]  B. Amsden,et al.  Solute Diffusion within Hydrogels. Mechanisms and Models , 1998 .

[57]  Yiyun Huang,et al.  Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma , 2013, Proceedings of the National Academy of Sciences.

[58]  木下 学.  Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption , 2007 .

[59]  Hsin-Ell Wang,et al.  Pulsed high-intensity focused ultrasound enhances the relative permeability of the blood–tumor barrier in a glioma-bearing rat model , 2011, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.